Compare Stocks → Chances are you know the firms on this list (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGTCNASDAQ:BVXVNASDAQ:CSBRNASDAQ:ONVO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/ABVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsCSBRChampions Oncology$5.07+0.8%$10.15$7.19▼$14.68$68.83M0.392,908 shs1,206 shsONVOOrganovo$1.15+2.7%$1.04$0.89▼$2.23$11.55M0.91863,510 shs578,990 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-30.26%CSBRChampions Oncology-1.76%+0.60%-3.64%-26.14%-9.04%ONVOOrganovo-2.61%+8.74%+0.90%+7.69%-48.15%Start loving Mondays like this (Ad)Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!Weekend after weekend!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACSBRChampions Oncology3.6673 of 5 stars3.34.00.04.60.62.50.0ONVOOrganovo0.4595 of 5 stars0.03.00.00.02.90.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic TechnologiesN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/ACSBRChampions Oncology2.50Moderate Buy$7.5048.08% UpsideONVOOrganovoN/AN/AN/AN/ACurrent Analyst RatingsLatest CSBR, BVXV, AGTC, and ONVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/ACSBRChampions Oncology$53.87M1.28N/AN/A$0.34 per share14.90ONVOOrganovo$370K31.21N/AN/A$1.76 per share0.65Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/ABVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/ACSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)Latest CSBR, BVXV, AGTC, and ONVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q3 2024CSBRChampions OncologyN/A-$0.19-$0.19-$0.19N/A$12.02 million2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40BVXVBiondVax PharmaceuticalsN/A4.124.12CSBRChampions OncologyN/A0.600.60ONVOOrganovoN/A3.673.67OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%BVXVBiondVax Pharmaceuticals11.83%CSBRChampions Oncology41.30%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%BVXVBiondVax Pharmaceuticals6.03%CSBRChampions Oncology45.69%ONVOOrganovo4.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableONVOOrganovo1810.04 million9.64 millionOptionableCSBR, BVXV, AGTC, and ONVO HeadlinesSourceHeadlineOrganovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 18 at 2:24 AMOrganovo's drug significantly reduces liver fat in NASH studyhealth.economictimes.indiatimes.com - April 16 at 9:35 AMWhy Organovo Stock Is Up Todaymsn.com - April 15 at 2:40 PMOrganovo’s fatty liver disease drug meets main goal in mid-stage studykfgo.com - April 15 at 9:40 AMOrganovo's fatty liver disease drug meets main goal in mid-stage studyreuters.com - April 15 at 8:28 AMOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placeboglobenewswire.com - April 15 at 8:05 AMStockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)americanbankingnews.com - April 10 at 2:18 AMOrganovo files patent for farnesoid x receptor agonist compound for treating diseasespharmaceutical-technology.com - March 24 at 6:42 PMOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning Callsbenzinga.com - February 24 at 7:35 AMOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - February 10 at 2:25 PMOrganovo Holdings Inc ONVOmorningstar.com - February 9 at 7:39 PMONVO Continues Progressfinance.yahoo.com - February 9 at 2:38 PMOrganovo: Fiscal Q3 Earnings Snapshotsfgate.com - February 8 at 7:40 PMOrganovo Holdings Unveils Corporate Presentation Onlinemsn.com - February 8 at 9:38 AMOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congressfinance.yahoo.com - January 25 at 12:43 PMOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congressfinance.yahoo.com - January 9 at 9:33 AMONVO Shares Experience Surge in Valueknoxdaily.com - January 4 at 10:15 AMChecking in on Organovo Holdings Inc (ONVO) after recent insiders movementknoxdaily.com - January 1 at 6:27 PMOrganovo Holdings: Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibitscbonds.com - December 30 at 8:48 AMOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinanznachrichten.de - December 7 at 8:37 AMOrganovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinance.yahoo.com - December 6 at 9:16 AMOVNO Continues Developing Breakthrough Treatmentsmsn.com - November 13 at 4:20 PMCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Planfinance.yahoo.com - November 13 at 8:43 AMOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)finance.yahoo.com - November 11 at 9:02 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.